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Full Paper
This paper describes the use of multivariate statistical
procedure PCA as a tool to explore the inhibitory activity
of classes of NNRTIs against HIV-1 viruses (wild type and
more frequent mutants, Y181C, V106A, K103N, L100I)
and against RT enzyme. The analysis of correlations
between biological activity and molecular descriptors or
similarity indexes allowed a reliable classification of the
fifty five derivatives considered in this study. The best
results were obtained in the case of L100I and K103N
mutants for which the higher number of assignments was
found when the principal components derived from the
descriptors were used. On this basis this statistical
approach is proposed as a reliable method for the
prediction of the activity of NNRTIs, for which the data
against mutant strains have not been reported.
1 Introduction
The treatment regimens for the human immunodeficiency
virus (HIV-1) have included bothHIV protease and reverse
transcriptase (RT) enzyme inhibitors. All antiretroviral
drugs currently approved for clinical use aredirected against
one of these targets. The first RT inhibitors approved in
USA and in Europe were nucleoside derivatives (NRTIs)
which compete with normal nucleoside substrates for
incorporation into the viral genome, thus behaving as chain
terminators [1]. Unlike nucleoside analogs, non-nucleoside
reverse transcriptase inhibitors (NNRTIs) bind in a non-
competitive manner to a specific ™pocket∫ of the HIV-1 RT,
which is closely associated with, but distinct from the
substrate binding site, altering its ability to function [2].
Nevirapine, Delavirdine, and Efavirenz are the only
NNRTIs that have received regulatory approval, whereas
several other inhibitors (MKC-442, PNU-142721, and so on)
are currently undergoing clinical trials.
Although current NNRTIs have demonstrated potent
antiviral activity in vitro and in HIV-1 infected patients,
mutations of the reverse transcriptase enzyme associated
with NNRTI therapy represent a major problem in devel-
oping resistance to current drugs regimens and they limit
enormously the effectiveness of the treatment. A single
mutation in the NNRTI-binding pocket may result in high-
level resistance to one or more NNRTIs. Therefore a high
priority for medical research remains the discovery of
antiviral agents effective against mutant HIV strains.
In this paper we propose the multivariate statistical
procedure, called PCA (principal component analysis), as a
tool to exploit the enormous amount of information
available on the inhibitory activity against HIV-1 viruses
(wild type and the more frequent mutants, Y181C, V106A,
K103N, L100I) and against RTenzyme.
Biological problems have an intrinsicmultivariate nature,
involving many variables at the same time, and in general
the relation between these variables and the biological
response is hidden and no useful information can easily be
extracted. In order to simplify the data set in a multivariate
problem and to obtain an informative picture of the data
tendencies, a chemometric multivariate analysis can be
used.
In the past multivariate data analysis has been applied in
many fields of science demonstrating to be most suitable in
handling complex data sets and allowing to investigate
relationships among all objects and all variables simulta-
neously. In particular PCA is able to detect similarities
among variables and is used to reduce the number of
variable thus preparing the data for further analysis. The
easier mathematical way to represent a multivariate prob-
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lem is to build a matrix relating variables and objects. In our
case the objects are the NNRTIs, the variables are selected
chemicals descriptors, and the biological response are IC50
against RTand susceptibility/resistance data.
Each object is now placed in an n-dimensional space
(where n is the number of variables). However is more
practical for us work in two or three dimensions. The PCA
permits the projection of higher order space in two or three
dimensions with a minimal loss of statistic information. The
coordinate axes of the original n-order space are rotated
until the direction of maximum variance is coincident with
one of the rotated axes (called the first principal component
axis). The second principal component and so on give the
orthogonal direction of the maximum residual variance.
Another interesting aspect in a chemometric multivariate
analysis is the possibility of classification as done in the
discriminant analysis (DA). The derived classification rule
describes a surface which separates the classes and it may be
used to predict class membership.
It is our aim to develop a simple but efficient method to
evaluate, on the basis of chemical-physical descriptors and
structural similarity, new NNRTIs that are less likely to
trigger resistance or are effective against mutant HIV
strains.
2 Materials and Methods
More than 30 different classes of NNRTIs have been
described to date. In this study fifty five NNRTI derivatives,
the structures of which are depicted in Figure 1, were
utilized. The selection includes most of the derivatives
currently present into the database of the National Institute
of Allergy and Infectious Diseases (NIAID) [3], and the
literature derivatives for which the inhibitory concentration
against RT enzyme (IC50, M) was reported [4]. The most
active compounds of each class were considered. Table 1
shows these activity values, to be included in the calcu-
lations, together with the available data on resistance/
susceptibility to the more frequent RT single mutant strains
which might confer NNRTI-resistance, reported in litera-
ture [5].
The compounds were divided into two classes of activity:
high [(H), (IC50 up to 0.095 M)] and low [(L), (IC50
0.095 M)]. The 3D structures of all the derivatives were
constructed and optimized by semiempirical methods
(MNDO or PM3). For chiral derivatives on which the
stereochemistry of the active form is not known both
enantiomers were considered (cf. entries 5/6; 27/28; 33/34;
43/44; 48/49).
A selected set ofmolecular descriptors, which identify the
molecular characteristics that can be related to the bio-
logical activity,were calculated (ellipsoidal volume, logP,H-
bond donors, H-bond acceptors, total lipole, surface area,
heat of formation, ELUMO, EHOMO, total dipole moment, total
energy in water) [6] and included in the database (Table 2).
Our selection of structural variables was made regarding
several reported x-ray crystallographic structures of HIV-1
NNRT inhibitors complexes which supported the already
well acknowledged binding mode of the different classes of
NNRTIs. In particular ellipsoidal volume, which is defined
by the moments of inertia, and accessible surface area give
information about steric properties of a molecule, log P is a
typical QSAR variable, related to hydrophobic/hydrophilic
profile of the inhibitor and in our case can be related to this
kind of interaction in the active site, total lipole is a measure
of the lipophilic distribution in a 3Dspace and it is calculated
from the summed atomic log P values, the number of H-
bond donors and acceptors give other information about the
ability of the inhibitor to stabilize its interaction with the
™binding pocket∫, total dipole gives information about the
electronic features, ELUMO and EHOMO are energetic varia-
bles that classify the set of the inhibitors in terms of their
ability to act as electrophiles and nucleophiles, as expected
for the inhibition process.Other energy variables are heat of
formation, which classifies the set of the inhibitors in terms
of relative thermodynamic stability and is widely used in
chemometric studies, and total energy in water which
classifies the behaviour of the inhibitors in the physiological
solvent.
The whole set of 11 descriptors and 55 compounds was
used to perform the PCA. Table 3 reports the matrix of
eleven PCs with their composition in terms of original
variables, together with the fraction of variance explained,
the total fraction of variance explained, and the eigenvalue
of the covariance matrix corresponding to each component
that is equal to the fraction of variance explained by the
number of variable used. The data were standardized by
mean/sd (standard deviation). The first four PCswhich have
eigenvalue  1 and explaining 73.7% of variance, were
selected for further calculations.
In the first PC the variables that have major importance
are ellipsoidal volume ( 0.39), surface area ( 0.45), and
total energy in water ( 0.46). These variables clearly
reflect the importance of steric approach to the binding
pocket and the behaviour of the molecule within the
cytoplasm. In the second PC electronics features have the
greaterweight: ELUMO ( 0.45),EHOMO ( 0.45), total dipole
moment ( 0.47), reflecting the importance of  stacking
during the interaction drug-receptor. Log P and heat of
formation have great importance in the third and in the
fourth PC ( 0.59,  0.44 and  0.38,  0.58 respectively),
in the same fashion the number of H-bond donors ( 0.41)
has importance in the third PC, and ELUMO ( 0.47) in the
fourth. But since the fraction of variance explained by the
third and the fourth PC is rather low, these variables are not
surely the most relevant.
Sincemolecular similarity is one of themost useful tool in
computer aided approach to discover molecules which bind
to the same receptor site, we also calculated the Carbo
similarity indexes [7] with flexible optimization in terms of
steric feature (shape) and lipophilic potential [6, 8]. In fact
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Table 1. RT inhibitory concentrations of NNRTIs and restistance (R)a/susceptibility (S)b to selected RT-mutants
Entry Derivative IC50 (M) Ref. L100I K103N V106A Y181C Activity data Ref.
1 ()12-OXOCALANOLIDE 40 4e R R S EC50 3
2 21-AAP-BHAP 0.098 4b S IC50 4b
3 ADAM-II 0.3 4b R R EC50 4b
4 AN-29-PNU-32945 50 4b
5 BENZOTHIADIAZINE-2(R) 4.627 4c
6 BENZOTHIADIAZINE-2(S) 4.627 4c
7 BM-510836 0.016 4f
8 CALANOLIDE-A 0.07 4a R R S EC50 4a
9 COMPD-1 1.5 4a
10 COMPD-2 28 4a
11 COMPD-36 0.21 4b S IC50 4b
12 COSTATOLIDE 0.003 4b R R S EC50 3
13 DABO-12e 1.8 4a
14 DAMNI-6D 0.05 4g
15 DELAVIRDINE 0.26 4f S R R R EC50 5c,5d
16 DIHYDROCOSTATOLIDE 0.003 4b R R S EC50 3
17 DPC-082 4b
18 DPC-961 0.031 4b S EC50 4b
19 E-EBU-dM 0.036 4f R vitro 5a,5b
20 EFAVIRENZ 0.003 4f R R S S EC50 3,5d,5c
21 GCA-186 4b R R EC50 4f
22 HBY-097 0.08 4f R EC50 4f
23 INOPHYLLUM-B 0.038 4a
24 IPPH 0.0006 4a
25 L-697661 0.019 4a S S R vitro 5a,5b
26 L-737126 0.003 4a
27 LOVIRIDE(R) 0.2 4a S R vitro 5a,5b
28 LOVIRIDE(S) 0.2 4a S R vitro 5a,5b
29 MKC-442 0.012 4a R R EC50 4a
30 MSA-300 4a
31 NEVIRAPINE 0.084 4f S R R R EC50 3
32 NPPS 0.61 4a
33 NSC-625487(R) 0.5 4a
34 NSC-625487(S) 0.5 4a
35 PBD 0.115 4a
36 PBO-13B(R) 4b S S S Ki 4b
37 PBO-13B(S) 4b S S S Ki 4b
38 PEQ 0.012 4a
39 PHS 0.64 4a
40 PNU-142721(R) 0.085 4b R IC50 4b
41 PNU-142721(S) 0.02 4b S S IC50 4b
42 PNU-32945 2.31 4b
43 PPO-13I(R) 4b S S S Ki 4b
44 PPO-13I(S) 4b S S S Ki 4b
45 QM-99639 15.1 4b S R R EC50 4b
46 S-2720 0.1 4f R vitro 5a,5b
47 SEFAVIRENZ 4b
48 TGG-II-23A(R) 136 4a
49 TGG-II-23A(S) 136 4a
50 TIVIRAPINE 0.05 4a R vitro 5a,5b
51 TNK-6123 4b S S EC50 4b
52 TTD-6G 16.4 4h S R R EC50 4 h
53 UC-781 0.059 4a R R S EC50 4a
54 UC-84 1.5 4a R R vitro 5a,5b
55 UK-129485 0.156 4a
aR 15 fold resistant ratio (Activity on mutant strain/Activity on wt); bS 15 fold resistant ratio.
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Table 2. Calculated molecular descriptors for NNRTI derivatives
Entry Descriptors
1 2 3 4 5 6 7 8 9 10 11
1 628.9 3.2 0 5 5.51 403.8  143.82  0.859  8.922 8.45  4748.8
2 3000.0 2.4 2 4 17.72 515.5  8.08  0.630  8.831 5.59  5692.5
3 1652.6 4.4 0 8 7.09 547.3  282.18  0.783  9.420 2.42
4 614.3 4.8 1 2 13.19 351.4 60.09  0.160  8.878 3.01  3440.1
5 763.5 2.8 2 2 9.28 339.5 25.05  0.672  9.276 3.77  3774.8
6 763.5 2.8 2 2 9.28 339.5 25.05  0.672  9.276 3.77  3774.8
7 578.3 4.8 0 1 6.86 322.6 38.24  0.599  8.728 2.44  3259.0
8 654.3 3.3 1 5 5.33 410.9  167.61  0.763  8.826 6.25  4776.9
9 351.4 1.0 0 3 4.40 265.5  4.28  0.706  9.479 5.53  3396.7
10 300.8 1.5 1 1 6.28 235.0 51.25  0.311  7.909 2.37  2601.4
11 5434.5 2.0 3 4 19.97
12 654.9 3.3 1 5 5.33 411.3  167.61  0.764  8.827 6.26  4776.9
13 691.0 3.5 1 3 8.15 358.2  49.34  0.230  9.245 4.11  3665.4
14 743.5 4.3 0 4 13.28 377.3 64.29  0.870  9.582 4.99  4270.9
15 3450.6 0.7 3 4 10.59 492.3 10.13  0.636  8.559 7.65  5603.0
16 623.4 3.4 1 5 4.93 415.5  195.20  0.705  8.932 6.92  4805.4
17 638.3 3.0 2 1 6.13 297.7  198.04  0.803  9.318 3.69  5102.7
18 735.3 3.0 2 1 7.08 300.7  81.49  0.529  9.196 4.04  4491.2
19 839.3 2.8 1 3 11.25 373.6  102.35  0.190  9.374 4.12  4011.1
20 674.7 3.6 1 2 5.48 297.6  120.15  0.749  9.454 5.36  4590.7
21 875.0 3.1 1 3 11.39 389.5  104.31  0.185  9.370 3.90  4166.5
22 1002.9 2.4 1 4 2.10 369.6  63.41  0.844  8.454 5.45  3959.0
23 712.4 3.8 1 5 8.93 426.0  118.05  0.860  8.803 6.27  5132.1
24 3281.9 4.8 0 4 7.20 455.3 131.06  0.888  8.641 3.99  4650.8
25 1012.3 1.3 2 3 15.68 358.2  0.77  0.781  8.197 3.36  4265.1
26 807.7 1.8 2 3 10.77 311.9  26.68  0.990  9.349 3.77  4014.4
27 702.8 2.9 2 2 5.29 351.4  38.49  0.424  8.671 2.65  4199.5
28 702.8 2.9 2 2 5.29 351.4  38.49  0.424  8.671 2.65  4199.5
29 638.1 2.2 1 3 9.49 345.4  89.08  0.218  9.406 3.56  3854.8
30 2512.9 3.4 3 5 14.28 396.6  3.11  0.586  8.369 5.42  4705.8
31 421.9 1.9 1 3 1.98 287.4 87.90  0.564  8.902 3.19  3258.8
32 601.2 2.8 0 4 7.10 244.5 6.97  1.404  10.395 9.37  3338.6
33 375.9 4.1 0 1 4.69 279.5 29.32  0.785  8.972 3.21  3633.9
34 375.9 4.1 0 1 4.69 279.5 29.32  0.785  8.972 3.21  3633.9
35 1793.4 3.0 1 3 7.48 370.9  11.47  0.267  8.458 1.73  4310.4
36 804.1 4.1 0 3 5.20 356.7 10.96  0.475  8.964 2.31  4115.2
37 806.7 4.1 0 3 5.20 356.7 10.96  0.476  8.964 2.32  4115.3
38 876.9 3.3 2 2 9.88 339.8 115.59  0.501  8.922 2.15  3808.9
39 584.6 2.8 0 4 9.14 366.5  114.99 0.212  8.984 3.80  4082.7
40 1636.5 3.2 1 4 3.71 304.8 72.63  0.472  8.545 5.90  3530.7
41 913.8 3.2 1 4 3.65 304.4 72.03  0.427  8.558 2.15  3530.7
42 524.2 4.4 0 2 7.45 318.3 149.51  0.279  9.099 4.18  3128.3
43 612.2 3.5 0 3 4.15 321.7 62.54  0.746  9.078 3.57  3704.0
44 612.2 3.5 0 3 4.15 321.7 62.54  0.746  9.078 3.57  3704.0
45 553.7 1.8 0 4 6.32 309.8  32.82  1.121  9.528 5.65  4385.8
46 539.3 2.8 1 3 5.95 322.4 2.74  1.015  8.747 2.84  3620.0
47 737.5 4.7 1 2 4.64 311.9  57.06  1.070  9.230 5.69  4463.7
48 494.4 2.9 0 3 6.84 313.8  14.20  0.746  9.285 3.55  3284.9
49 494.4 2.9 0 3 6.84 313.8  14.20  0.746  9.285 3.55  3284.9
50 682.2 3.8 1 2 3.54 345.9 74.37  0.616  8.400 3.33  3511.2
51 511.3 3.1 1 3 6.92 375.7  131.61  0.680  9.054 3.70  3978.7
52 451.3 1.7 0 4 5.96 304.6 12.13  1.048  9.584 5.35  3913.7
53 1420.7 4.6 1 3 4.90 367.4 12.25  0.948  8.494 5.51  3839.4
54 1610.2 1.1 1 4 13.32 370.7  128.30  0.419  8.573 6.54  4354.3
55 536.8 3.6 0 4 5.19 334.0 112.75  0.599  8.495 2.53  3762.5
Value were obtained by using numerical algorithms included in TSAR 3.2 package: 1. Ellipsoidal volume(ä3), 2. log P, 3. number of H-bond donors, 4.
number of H-bond acceptors, 5. total lipole, 6. surface area (ä2), 7. heat of formation (kcal mol-1), 8. ELUMO (eV), 9. EHOMO (eV), 10. total dipole moment
(Debye), 11. total energy (eV).
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the shape could provide information on the accessibility and
interaction with the active site, whereas the lipophilicity can
be important not only for the interaction with the binding
site, which is stabilized by hydrophobic features of the
inhibitor, but also for the bioavailability.
The measure of similarity between two molecules, based
on the physical properties of lipophilicity, shape, electro-
static potential and so on, was obtained by using an
analytical approach in which Gaussian functions are sub-
stituted into the calculation equations. The properties were
compared throughout space, using an infinitesimal grid
increment.Molecular similarity indexes are very sensitive to
the relative orientation of the two compounds and depend
on pair wise molecular superimpositioning. The optimiza-
tion was achieved by rotation and translation of the
molecules for comparison and by altering the conformation
of these molecules (flexible optimization).
Again a PCAwas carried out on thematrices of similarity
indexes and the number of significant PCs was determined
as above (eigenvalue  1). These PCs (8 in the case of
similarity index according to shape and 2 in the case of
similarity index according to lipophilicity) were considered
(cf Table 3).
Therefore the PCs selected for descriptors and similarity
indexes were separately included in a discriminant analysis
(DA)with the aimofproviding assignment to the two classes
of activity H or L. By using the Mahalanobis distance
discrimination algorithm and the procedure reported by
Manly [9], the TSAR automatic procedure was selected as
stopping procedure. This ends when all the points are
correctly classified (no variable will give more than 5%
increase in the total Mahalanobis distance sum between
class centers and the best variable reduces the total number
of well-classified points) or all the variables have been
added. A data point is considered to be well-classified if the
classification rule derived by the DA predicts that point to
belong to its true class. A summary of the results achieved
with DA is reported in Table 4 that lists the total number of
compounds predicted to belong to each class (H or L),
brokendownby the true class of each individual, the final set
of PCs included in each case, together with the partial hit-
rate. Themean of the partial hit-rates gives the total hit-rate
(percentage of statistical units correctly classified by the
discriminant function). This last is an estimate of the true
predictive ability of the model which was validated by
Huberty×s tests [proportional chance (Cpro) and maximum
chance (Cmax)] [10]. The proportional chance criterion for
assessing model fit is calculated by summing the squared
proportion that each group represents of the sample (Eq. 1).
The maximum chance criterion is the proportion of cases in
the largest group (Eq. 2).
Cpro p2 (1 p)2 (1)
p proportion of subjects in one group
(1 p) proportion of cases in the other group
Cmax (nL/NL) (100) (2)
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Table 3. Results of PCA on the reduced set of descriptors and similarity indexes
Descriptor PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 PC11
1 0.386 0.238 0.259  0.319  0.096 0.052  0.494  0.111 0.216  0.424 0.357
2  0.140 0.034 0.589 0.438  0.350 0.338 0.069 0.371  0.143  0.195 0.015
3 0.278 0.302  0.408  0.150 0.043 0.436  0.016 0.329  0.580 0.013 0.052
4 0.331  0.262 0.272  0.027 0.257  0.487 0.232 0.013  0.517  0.344  0.033
5 0.288 0.223  0.224  0.083  0.607  0.290 0.497 0.172 0.246  0.128  0.052
6 0.450 0.124 0.267 0.213  0.053  0.067 0.057  0.191  0.080 0.707 0.331
7  0.227 0.281 0.385  0.581  0.201  0.121  0.084  0.026  0.234 0.275  0.434
8  0.027 0.454  0.150 0.473 0.035  0.485  0.471 0.171  0.064  0.008  0.228
9 0.094 0.453 0.225  0.037 0.619 0.095 0.366 0.239 0.365  0.025  0.119
10 0.293  0.467 0.025  0.153 0.026  0.053  0.281 0.655 0.249 0.246  0.189
11  0.457 0.075  0.010  0.203 0.046  0.321 0.055 0.396  0.070 0.092 0.681
Fraction of variance explained 0.327 0.194 0.120 0.095 0.083 0.075 0.031 0.029 0.022 0.010 0.009
Total variance explained 0.327 0.521 0.642 0.737 0.820 0.896 0.927 0.957 0.979 0.991 1
Eigenvalue 3.602 2.137 1.325 1.046 0.917 0.834 0.341 0.326 0.246 0.120 0.100
Shape PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8
Fraction of variance explained 0.529 0.118 0.091 0.045 0.034 0.029 0.020 0.019
Total variance explained 0.529 0.647 0.739 0.784 0.819 0.848 0.869 0.889
Eigenvalue 29.130 6.491 5.050 2.498 1.892 1.608 1.137 1.082
Lipophilicity PC1 PC2
Fraction of variance explained 0.947 0.024
Total variance explained 0.947 0.971
Eigenvalue 52.1 1.33
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nL number of subjects in the larger of the two groups
NL total number of subjects into combined groups
The classification accuracy of themodel should result one
fourth greater than that achieved by chance (min. hit-rate).
The other validation test we used in this analysis is
Pearson×s chi-square (Chi2) [11]. The chi-square test of
statistical significance is a series of mathematical formulas
which compare the actual observed frequencies of some
phenomenon (in our sample) with the frequencies wewould
expect if there were no relationship at all between the two
variables in the larger (sampled) population. Therefore, chi-
square tests the actual results against the null-hypothesis
and assesses whether they are different enough to overcome
a certain probability that they are due to sampling error.
3 Results and Discussion
Data reported in Table 4 show the results of the classifica-
tion obtainedwhen evaluating the inhibitory activity against
RTenzyme. After selecting the appropriate number of PCs
as reported in the previous section and excluding the entries
exhibiting missing values, the discriminant analyses provid-
ed a good assignment of the derivatives to the two classes of
activity. In particular if shape is considered, the model
correctly classifies both high and low active compounds, on
the basis of the 8 PCs (explaining 89% of variance). An hit-
rate 74.4% demonstrated the predictivity of the model,
whereas in the case of similarity index based on lipophilicity,
the hit-rate resulted lower (65.2%). In the case of PCs
derived from descriptors, when 4 PCs (eigenvalue  1, cfr
Table 3) are included in the calculations, the less active
compounds were well classified (partial hit-rate 75%); but a
lower value was obtained in the case of compounds
belonging to the H class. However the total hit-rate
(68.1%) results statistically significant. In fact based on
the requirement for the model accuracy (25% better than
Cpro) the standards to use for comparing the model
accuracies are 63.0% (descriptors), 63.2% (shape indexes),
63.5% (lipophilicity indexes). Our model accuracy rates
exceed these standards.With respect to theCmax ourmodel
accuracy rates exceed the standards in all the cases but for
lipophilicity indexes. However all the models present chi-
square  3.84 and p (probability value)  0.05 [as required
when df (degrees of freedom) 1].
According to the DA, besides entry 31 (Nevirapine), that
was always classified as low active probably because the IC50
is rather close to the value used for separating the two
classes, also for derivatives 50 (Tivirapine) and 53 (UC-781)
(in similarity indexes) and 25 (L-697661), in lipophilicity
index and descriptors, the misclassification as low active is
probably due to their neighbourhood to the cut-off point.
The analysis misclassified as high active derivatives 2 (21-
AAP-BHAP) for the same reason as above.Only for entries
20 (Efavirenz), 24 (IPPH), 26 (L-737126), the misclassifica-
tion is not justified by this assumption.
Based on descriptors the misclassification as high active
involves entries 15 (Delavirdine), 35 (PBD), 42 (PNU-
32945), and 55 (UK-129485), whereas as far as the similarity
index based on shape was concerned the same type of
misclassification involved derivatives 10 (Compd 2), 15
(Delavirdine), 27/28 (Loviride), and 54 (UC-84). In the
analysis based on lipophilicity indexes the entries 2, 4, 5/6, 9,
10, 13, 42were classified as high active. 12-Oxocalanolide (1)
was always classified as high active although the IC50 was
40 M, probably because of the obvious structural similarity
with Calanolide (8), Costatolide (12) and Dihydrocostato-
lide (16) that were all correctly assigned to the expected H
class.
Since most NNRTIs bind to the same enzyme×s pocket,
structural requirements are very strict and it is particularly
significant that the best results (higher hit-rate) are obtained
when the shape was considered. Therefore the inhibitory
activity of this series of NNRTIs can be properly described
on the basis of the statistical approach outlined so far.
The next step was to demonstrate that PCA can be used
when the activity or inactivity against the RT mutant was
considered. To this purpose the available data on the activity
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Table 4. Results of DAa based on PCs for descriptors and similarity indexes for classes H and L
Descriptors Similarity index SHAPE Similarity index LIPOPHILICITY
Predicted Total Hit-Rate Predicted Total Hit-Rate Predicted Total Hit-Rate
L H L H L H
L 18 6 24 75.0% 18 6 24 75.0% 17 9 26 65.3%
H 8 12 20 60.0% 5 14 19 73.6% 7 13 20 65.0%
Total 26 18 44b 68.1% 23 20 43c 74.4% 24 22 46d 65.2%
Included variables PC1, PC2, PC3 PC4, PC6, PC8 PC1, PC2
Chi2 5.52; df 1, p 0.025 10.10; df 1, p 0.01 4.18; df 1, p 0.05
Cpro 50.4% min. hit-rate 63.0% 50.6% min. hit-rate 63.2% 50.8% min. hit-rate 63.5%
Cmax 54.5% min. hit-rate 64.0% 55.8% min. hit-rate 69.7% 56.5% min. hit-rate 70.6%
a Cross validation employed: leave out 1 row in turn. b Excluded entries: 3, 11, 17, 21, 30, 36, 37, 43, 44, 47, 51. c Excluded entries: 11, 14, 17, 21, 30, 36, 37, 39,
43, 44, 47, 51. d Excluded entries: 17, 21, 30, 36, 37, 43, 44, 47, 51.
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against the more common HIV-1 mutants were considered
for calculation. These data include the inhibitory activity
measured against the cells infectedwithmutated virus (EC50
values) or against mutated RTenzyme (IC50 or Ki values) or
other in vitro tests (cfr Table 1).
It is well known that a single mutation in the NNRTI-
binding pocket may result in high-level resistance to one or
more NNRTIs. The RT mutations selected in this paper are
K103N and Y181C, associated with resistance to NNRTIs
which compromise the antiviral activity of first generationof
NNRTIs [4b], including the available drugs [(15) Delavir-
dine, (31) Nevirapine], and V106A and L100I which cause
resistance also to the newer generations of NNRTIs,
although from low to intermediate in the case of (15)
Delavirdine and (20) Efavirenz [12, 13].
This time the NNRTIs were classified as susceptible (S)/
resistant (R) against the single mutant strain [5] and theDA
was carried out considering in turn only the derivatives for
which the data on resistance/susceptibility were available
(cfr Table 1). The results of these discriminant analyses are
summarized in Table 5. The hit-rates obtained in these cases
were generally very good ( 80.9) especially for the
susceptible compounds: correct assignment to the classes
was achieved with very few exceptions. These findings were
particularly significant in the case of the two more frequent
mutants (L100I and K103N), when the PCs derived from
descriptors and shape similarity index are considered.When
the similarity indexes based on lipophilicity were used the
hit-rate had statistic significance only in the case of L100I
mutant. Taking in account the PCs derived from descriptors
it is relevant to observe that in the case of L100I and K103N
mutations, the first two principal components have a major
weight evidencing thus the importance of shape and
electronics features in the arising resistance. In the case of
Y181Cmutation again the first PC ismainly involved, but an
important role has the third and the fourth PC (log P, heat of
formation, but also ELUMO and H-bond donors). In the case
of V106Amutation the second, the third, the fourth PCs are
relevant sowe can assume that electronics features carry out
a role of primary importance.
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Table 5. Results of DAa based on PCs for descriptors and similarity indexes for classes R and S
Descriptors Similarity index SHAPE Similarity index LIPOPHILICITY
Predicted Tot. Hit Rate Predicted Tot. Hit Rate Predicted Tot. Hit Rate
R S R S R S
R 6 1 7 85.7% 7 0 7 100% 6 1 7 85.7%
L S 0 10 10 100% 0 10 10 100% 1 9 10 90.0%
1 Total 6 11 17 94.1% 7 10 17 100% 7 10 17 88.2%
0 Included variables PC1, PC2, PC4 PC4, PC6, PC7 PC2
0 Chi2 13.24; df 1, p 0.001 17; df 1, p 0.001 9.74; df 1, p 0.01
I Cpro 51.5% min. hit-rate 64.3% 51.5% min. hit-rate 64.3% 51.5% min. hit-rate 64.3%
Cmax 58.8% min. hit-rate 73.5% 58.8% min. hit-rate 73.5% 58.8% min. hit-rate 73.5%
R 11 4 15 73.3% 14 2 16 87.5% 15 1 16 93.7%
K S 0 8 8 100% 0 8 8 100% 7 1 8 12.5%
1 Total 11 12 23b 82.6% 14 10 24 91.6% 22 2 24 66.7%
0 Included variables PC1, PC2, PC4 PC3, PC4, PC5, PC8 PC1
3 Chi2 11.24; df 1, p 0.001 13.24; df 1, p 0.001 0.27; df 1, p 1
N Cpro 52.7% min. hit-rate 65.8% 55.5% min. hit-rate 69.7% 55.5% min. hit-rate 69.7%
Cmax 65.2% min. hit-rate 81.5% 66.7% min. hit-rate 83.3% 66.7% min. hit-rate 83.3%
R 4 0 4 100% 4 0 4 100% 2 2 4 50.0%
V S 0 5 5 100% 0 5 5 100% 0 5 5 100%
1 Total 4 5 9 100% 4 5 9 100% 2 7 9 77.8%
0 Included variables PC2, PC3, PC4 PC3 PC1, PC2
6 Chi2 9; df 1, p 0.01 9; df 1, p  0.01 3.21; df 1, p 0.1
A Cpro 50.5% min. hit-rate 63.1% 50.5% min. hit-rate 63.1% 50.5% min. hit-rate 63.1%
Cmax 55.5% min. hit-rate 69.4% 55.5% min. hit-rate 69.4% 55.5% min. hit-rate 69.4%
R 7 1 8 87.5% 5 3 8 62.5% 7 2 9 77.8%
Y S 1 11 12 91.6% 1 12 13 92.3% 7 6 13 46.1%
1 Total 8 12 20b, c 90.0% 6 15 21c 80.9% 14 8 22 59.1%
8 Included variables PC1, PC3, PC4 PC2, PC3, PC5, PC6, PC7 PC1, PC2
1 Chi2 13.24; df 1, p 0.001 7.28; df 1, p 0.01 1.31; df 1, p 1
C Cpro 52.0% min. hit-rate 65.0% 52.8% min. hit-rate 66.0% 51.6% min. hit-rate 64.5%
Cmax 60.0% min. hit-rate 75.0% 61.9% min. hit-rate 77.3% 59.0% min. hit-rate 73.7%
a Cross validation employed: leave out 1 row in turn. b Entry excluded: 3. c Entry excluded: 11
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Table 6. NNRTIs classification into classes R and S
Descriptors SHAPE
Entry L100I K103N V106A Y181C L100I K103N V106A Y181C
1 R R s S R R S
2 r r r S s r S
3 EXCLUDED R R
4 s s r
5 r r
6 r r
7 s s r r
8 R R S R R S
9 s r r r
10 s r s
11 EXCLUDED EXCLUDED
12 R R S R R S
13 s r
14 s r s s EXCLUDED
15 S R R R S R R R
16 R R s S R R S
17 r r
18 S r s
19 s r r r R r
20 R R s S r r s s
21 R R R r R
22 s R R r r
23 r r s r r s
24 s s s r
25 S s r R s s R
26 s r r
27 S R S R
28 S R S R
29 R R r r R
30 s r r
31 S r R r s r R r
32 s r r
33 s s
34 s s
35 s r s
36 s S S S S S
37 s S S S S S
38 s r
39 r s s s EXCLUDED
40 s r s R
41 S s s S s S
42 s s r
43 S s S S S S
44 S s S S S S
45 S R r S r r
46 s r r
47 r r s s
48 s
49 s
50 R s R r
51 r R r R r R
52 S R R S R s r
53 R r s s r R S
54 r r r R r R
55 s s
R, S: correct; r, s: predicted; R, S: misclassified opposite class; r, s: misclassified no-data class
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On the basis of the above results new calculations were
carried out also including this time the derivatives for which
data against mutant are not available and excluding entries
exhibiting missing values. The classification procedure, in
the present case, implies the fitting of compounds unclassi-
fied against each RT mutant into the classes S (susceptible)
or R (resistant). Data reported in Table 6 show that it was
possible to provide predictions on the activity of several
derivatives assigning up to 10 compounds to the class R,
whereas it has to be expected that an even higher number of
derivatives, classified asS, canmaintain their activity against
RT mutated strains. In general, the best results were
obtained in the case of L100I and K103Nmutants for which
the higher number of assignments was found when the
principal components derived from the molecular descrip-
tors was used. As far as V106A mutation is concerned the
predictions are less significant because of the small number
of input data available.
As far as the compounds classification is concerned, our
results can be summarized as follow:
1. Comparison of the results for all theRTmutants shows
that an unique consistent classification as S was
achieved in the case of derivatives 33, 34, 40, 41, 48,
49, 55 and asR in the case of compounds 5, 6, 17, 51, 54.
The following derivatives were generally classified as
susceptible but assignment was controversial against
K103N mutant, entries 4 and 42, or against V106A,
entry 24.
2. Derivatives 23, and 41 were always predicted to the
same class.
3. With regard to the 3 approved drugs, Delavirdine (15)
was generally correctly identified with the sole excep-
tion of shape similarity index and Y181C mutant;
Efavirenz (20) was generally classified correctly by the
PC derived from descriptors, whereas Nevirapine (31)
was well classified in the case of V106A mutant.
4. In the case of PNU-142721, the only compound under
clinical trial forwhich so far different inhibitory activity
and resistance/susceptibility data are available for the
two stereoisomers [entries 40 (R configuration) and 41
(S configuration)], the analyses involving the descrip-
tors and the shape similarity index in most cases were
able to discriminate between the two isomers. For the
other chiral compounds included in this study no
relevant differences were evidenced, confirming thus
the literature results of biological tests carried out on
the mixture of isomers.
4 Conclusions
On this basis themultivariate statistical procedure PCA can
be proposed as a reliable method for the prediction of the
activity of NNRTIs, for which the data against mutant
strains has not been reported.
Although this method implies some simplification of a
more complex problem (a wider or diverse choice of
descriptors could be considered) the approach proposed
by us can be used as a sufficiently good and fast discrim-
inator to preliminarily evaluate the probable emergence of
resistance to newer synthesized compounds before it is
actually verified in biological tests. This in silico screening
results not expensive and easily accessible to most of
researchers active in the field.
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